Avience Biomedicals IPO GMP today is Rs 187.2. Investors can use this GMP along with price band and subscription status for a better IPO review.
Listed
SME IPO
AVIENCE BOIMEDICALS
Avience Biomedicals IPO GMP & Allotment
Avience Biomedicals is a SME IPO with a price band of Rs 196.00 to Rs 208.00 that listed on 25 Jun 2026 at a listing gain of +90.00%. Track its full GMP history, subscription data and listing details here.
- IPO Price Band
- ₹196.00 - ₹208.00
- Lot Size
- 600 Shares
- Bidding Closes
- 22 Jun 2026
- Listing Date
- 25 Jun 2026
Quick Answer & Highlights
Avience Biomedicals IPO GMP Today & Key Takeaways
Last updated: 23 Jun 2026
Avience Biomedicals IPO officially listed on 25 Jun 2026 at Rs 395.20, delivering a +90.00% listing gain compared to its issue price of Rs 208.00. Pre-listing, its final recorded Grey Market Premium (GMP) was ₹187.2.
Avience Biomedicals IPO officially listed on 25 Jun 2026 at ₹395.20, delivering a +90.00% listing gain compared to its issue price of ₹208.00. Pre-listing, its final recorded Grey Market Premium (GMP) was ₹187.2.
| Key Metric | Figure | Status / Context |
|---|---|---|
| Current GMP | ₹187.2 | +90% vs upper band (23 Jun 2026) |
| Est. Listing Price | ₹395.20 | +90.00% Est. Listing Gain |
| Price Band | ₹196.00 - ₹208.00 | SME IPO |
| Retail Minimum Investment | ₹2,49,600 | 2 Lot (600 Shares) |
| Bidding Window | 18 Jun 2026 – 22 Jun 2026 | Listed |
| Allotment & Listing Dates | Allotment: 23 Jun 2026 | Listing: 25 Jun 2026 |
Current GMP Status
₹187.2
+90% vs upper band
Est. Listing Gain
+90.00%
Last Trend
23 Jun 2026
Listing Price
₹395.20
Retail Entry
₹2,49,600
IPO Details
Complete IPO information
| IPO Open Date | 18 Jun 2026 |
|---|---|
| IPO Close Date | 22 Jun 2026 |
| IPO Price Band | ₹196.00 - ₹208.00 |
| Lot Size | 600 Shares |
| Current GMP | ₹187.2 |
| Estimated Listing Gain | +90.00% |
| Issue Size | - |
| Fresh Issue | - |
| Issue Type | SME |
| IPO Listing | NSE, BSE |
| Retail Quota | TBA |
| Registrar | TBA |
| Overall Subscription | 43.79x |
| Minimum Investment | ₹2,49,600 |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus | - |
Analysis
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Avience Biomedicals is priced at ₹208 per share. With a minimum lot size of 600 shares, a retail investor applying for one lot would need approximately ₹2,49,600 to participate in this SME issue.
The latest recorded Grey Market Premium for Avience Biomedicals stands at ₹187.2, implying an estimated listing gain of around 90.00% over the issue price if it holds until listing. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Avience Biomedicals's IPO was subscribed 43.79x overall, with a category-wise breakdown of Retail 58.97x, QIB 0.03x.
SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.
Timeline
IPO roadmap at a glance
✓
Bidding Opens
18 Jun 2026
✓
Bidding Closes
22 Jun 2026
✓
Allotment
23 Jun 2026
✓
Listing
25 Jun 2026
| Event / Milestone | Scheduled Date | Status |
|---|---|---|
| Bidding Opens | 18 Jun 2026 | Completed |
| Bidding Closes | 22 Jun 2026 | Completed |
| Allotment | 23 Jun 2026 | Completed |
| Listing | 25 Jun 2026 | Completed |
Grey Market Premium
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 23 Jun 2026 | ₹70.00 | - | 33.65% |
| 22 Jun 2026 | ₹70.00 | -₹15.00 | 33.65% |
| 19 Jun 2026 | ₹85.00 | +₹10.00 | 40.87% |
| 18 Jun 2026 | ₹75.00 | - | 36.06% |
Swipe to see more →
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lot | 1,200 | ₹2,49,600 |
| Retail Maximum | 2 Lot | 1,200 | ₹2,49,600 |
| S-HNI Minimum | 3 Lot | 1,800 | ₹3,74,400 |
| S-HNI Maximum | 8 Lot | 4,800 | ₹9,98,400 |
| B-HNI Minimum | 9 Lot | 5,400 | ₹11,23,200 |
Swipe to see more →
Fund Utilization
Objects of the Issue & Official Documents
Analysis
Avience Biomedicals IPO Reservation
The Avience Biomedicals IPO allocation structure is divided among different investor categories such as QIB, NII, and retail investors. This structured distribution ensures balanced participation from institutional and individual investors during the subscription phase.
A significant portion of shares is allocated to retail investors, encouraging broader public participation, while institutional segments help provide stability and demand visibility for the issue.
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 4,09,800 Shares | 28.19% |
| QIB (Ex. Anchor) | 2,73,600 Shares | 18.82% |
| NII Shares Offered | 2,07,000 Shares | 14.24% |
| Retail Shares Offered | 4,81,200 Shares | 33.10% |
Analysis
Avience Biomedicals IPO Anchor Investors
The anchor investor segment of Avience Biomedicals IPO plays a key role in building early confidence for the issue. These investors participate before the public subscription window opens, helping establish initial demand visibility and pricing stability.
Lock-in requirements ensure that a portion of the anchor allocation remains invested for a defined period after listing, supporting market stability in the early trading phase.
| Particular | Details |
|---|---|
| Anchor Bidding Date | June 17, 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in (50% shares - 30 Days) | 2026 |
| Lock-in (50% shares - 90 Days) | 2026 |
Analysis
Avience Biomedicals IPO Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 18 Jun 2026 |
| IPO Close Date | 22 Jun 2026 |
| Basis of Allotment | 23 Jun 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 25 Jun 2026 |
Note: The timeline for Avience Biomedicals IPO is tentative and subject to change.
Analysis
Avience Biomedicals IPO Promoters and Holding Pattern
The promoter group of Avience Biomedicals consists of experienced individuals who are actively involved in managing the company’s operations and strategic growth. Their continued presence ensures stability in leadership even after the public issue.
Although the IPO introduces public shareholders, the promoters will retain a significant stake in the company post listing, ensuring strong control and long-term commitment to business expansion.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 40,31,256 | 87.89% |
| Promoter Holding Post Issue | 54,85,056 | 64.59% |
Analysis
Avience Biomedicals Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
Analysis
Avience Biomedicals - About IPO
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products.
Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
Analysis
Avience Biomedicals Company Financials
To Be Updated Soon
Analysis
Avience Biomedicals Company Valuation – FY2026
To Be Updated Soon
Analysis
Avience Biomedicals IPO Peer Group Comparison
To Be Updated Soon
Analysis
IPO Lead Managers aka Merchant Bankers
- Fintellectual Corporate Advisors Pvt. Ltd.
Comparison
Compare Avience Biomedicals IPO with similar IPOs
FAQ
Avience Biomedicals IPO FAQs
Based on the latest Grey Market Premium (GMP) of Rs 187.2 and an issue price of Rs 208, the estimated listing price for Avience Biomedicals IPO is Rs 395.20 (approx 90.00% listing gain). Actual listing price is determined by market demand on the listing day.
Avience Biomedicals IPO price band is Rs 196.00 to Rs 208.00. Check the latest issue price, lot size and GMP together before applying.
Avience Biomedicals IPO open date is 18 Jun 2026, close date is 22 Jun 2026, and listing date is 25 Jun 2026.
Avience Biomedicals IPO lot size is 600 shares. The minimum retail investment is Rs 2,49,600.
Avience Biomedicals is classified as a SME IPO. This helps investors quickly understand the issue category and exchange segment.
Avience Biomedicals IPO subscription status currently shows Retail 58.97x, QIB 0.03x, Overall 43.79x.
Avience Biomedicals IPO issue size is TBA and the expected allotment date is 23 Jun 2026.
In our empirical study of 117 Indian IPO listings, positive GMP was followed by a positive listing gain 69.8% of the time. However, as an exact forecast, the median variation between GMP-implied gain and actual listing price was 8 percentage points. GMP reflects informal market sentiment and should always be evaluated alongside company valuation and fundamentals.
Community discussion
Comments
Share a useful question or insight about Avience Biomedicals.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Keep Exploring
Similar Recent IPOs
SME
Vedant Poly Fabs
Price Band₹88.00 - ₹94.00
Current GMP₹1 · +1.1%
Lot Size1,200 Shares
SME
Johnsoncab Electricals
Price Band₹190.00 - ₹200.00
Current GMP₹8 · +4.0%
Lot Size600 Shares
SME
HGS (India)
Price Band₹114.00 - ₹120.00
Current GMP₹28 · +23.3%
Lot Size1,200 Shares
SME
Maxwell Engineering Solutions
Price Band₹150.00 - ₹158.00
Current GMP₹142.2 · +66.5%
Lot Size800 Shares
Loading comments...